Market closed · Next open: Thursday 9:30 AM ET
Last update: Nov 18, 2026, 6:18 PM ET
Market closed·93 changes confirmed today

Track the stock moves that actually matter.

BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.

1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
See all of today's movers: top gainers, losers and trending tickers →

Investment research built around change detection.

Showing:

BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.

✓Nov 18 session - Last update: Nov 18, 2026, 4:38 PM ET
SNEX
StoneX Group Inc.
$53.83
EPS surprise−25.00%
Nov 18, 2026 ET
⚠️Material / Earnings✓High confidence

What changed: StoneX Group Inc. (SNEX) reported EPS of $0.66 vs. consensus estimate of $0.88, missing by 25.0% on 2026-11-18.

Source: earnings_events

Changes History →
What's next

Monitor for any revised FY2026 guidance or management commentary on headwinds affecting near-term earnings.

✓Nov 18 session - Last update: Nov 18, 2026, 10:08 AM ET
TGT
Target Corporation
$165.96
EPS surprise+27.40%
Nov 18, 2026 ET
🏆Material / Earnings✓High confidence Research available →

What changed: Target Corporation (TGT) reported EPS of $2.65 vs. consensus estimate of $2.08, beating estimates by 27.4% on 2026-11-18.

Source: earnings_events

Changes History →
What's next

TGT earnings scheduled for 2027-03-02, with consensus EPS estimate of $2.70.

✓Nov 18 session - Last update: Nov 18, 2026, 4:38 PM ET
OKTA
Okta, Inc.
$195.61
▲ 9.90%
Prev close $177.99
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Okta, Inc. (OKTA) moved +9.90% from $177.99 to $195.61 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on elevated volume (2.3x the 5-day average), suggesting institutional interest, though the trigger remains unclear.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Okta's earnings announcement on 2026-12-01 (consensus EPS estimate $0.93) will test whether the stock's strength holds.

✓Nov 18 session - Last update: Nov 18, 2026, 4:38 PM ET
GNRC
Generac Holdings Inc.
$205.45
▲ 8.76%
Prev close $188.91
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Generac Holdings Inc. (GNRC) moved +8.76% from $188.91 to $205.45 on 2026-11-18 after the company's PWRmicro microinverter won Best in Show at the 2026 Solar Power World Top Products Awards. Volume traded was 2.3x the 5-day average, indicating elevated institutional interest.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

GNRC earnings scheduled for 2026-02-10 will provide updated guidance and shipment trends for the PWRmicro product line.

✓Nov 18 session - Last update: Nov 18, 2026, 4:38 PM ET
WWD
Woodward, Inc.
$319.07
EPS surprise+11.42%
Nov 18, 2026 ET
🏆Material / Earnings✓High confidence

What changed: Woodward, Inc. (WWD) reported EPS of $2.83 vs. consensus estimate of $2.54, beating by 11.4%.

Source: earnings_events

Changes History →
What's next

Monitor WWD's next earnings announcement (currently scheduled for 2026-11-23, pending confirmation) for guidance on sustaining this operational momentum.

✓Nov 18 session - Last update: Nov 18, 2026, 4:38 PM ET
P
Everpure, Inc.
$101.00
EPS surprise+10.82%
Nov 18, 2026 ET
🏆Material / Earnings✓High confidence

What changed: Everpure, Inc. (P) reported EPS of $0.86 vs. $0.78 consensus estimate, beating by 10.8% on 2026-11-18.

Source: earnings_events

Changes History →
What's next

P's next earnings announcement scheduled for 2026-12-01.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
M
Macy's, Inc.
$24.88
▲ 6.92%
Prev close $23.27
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Macy's, Inc. (M) moved +6.92% from $23.27 to $24.88 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was 1.6x the 5-day average, suggesting modest institutional interest ahead of the company's third-quarter 2026 earnings announcement scheduled for December 2, 2026.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Macy's third-quarter 2026 earnings announcement on December 2, 2026 — the consensus expects a loss per share; any beat could validate the pre-announcement move.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
KRMN
Karman Holdings Inc.
$34.19
▼ 5.16%
Prev close $36.05
Nov 18, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Karman Holdings Inc. (KRMN) moved -5.16% from $36.05 to $34.19 on 2026-11-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, suggesting modest institutional participation in the decline.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Karman Holdings' earnings announcement (scheduled for 2026-03-24, pending confirmation) with consensus EPS estimate of $0.23.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
CVLT
Commvault Systems, Inc.
$150.95
▲ 6.21%
Prev close $142.13
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Commvault Systems, Inc. (CVLT) moved +6.21% from $142.13 to $150.95 on 2026-11-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Monitor for CVLT earnings announcement on 2027-01-26 for confirmation of forward guidance and execution.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
EAT
Brinker International, Inc.
$203.43
▲ 5.10%
Prev close $193.56
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Brinker International, Inc. (EAT) moved +5.10% from $193.56 to $203.43 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on volume near its 5-day average.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Monitor the Q1 FY2027 earnings announcement (2027-01-27) against the consensus EPS estimate of $3.37 for confirmation of underlying momentum.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
OSCR
Oscar Health, Inc.
$27.57
▼ 7.58%
Prev close $29.83
Nov 18, 2026 ET
🛡Material / Earnings✓High confidence

What changed: Oscar Health, Inc. (OSCR) moved -7.58% from $29.83 to $27.57 on November 18, 2026, reaching a new 30-day low on modestly elevated volume (1.7x the 5-day average). The pullback followed a steep year-to-date run-up of roughly 95%–108% and occurred despite no major negative company announcement on the day itself. Profit-taking appears to have intensified after the stock slipped below its 50-day moving average earlier in November, with traders consolidating positions after the company's November 5 Q3 2026 earnings report (which raised full-year 2026 guidance for a third time) and amid investor caution around 2027 expansion execution and healthcare costs.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Oscar Health is scheduled to report Q4 2026 earnings on February 9, 2027 (consensus EPS estimate: −$1.08); watch for any updates on 2027 expansion progress and medical cost guidance.

✓Nov 18 session - Last update: Nov 18, 2026, 4:44 PM ET
SRRK
Scholar Rock Holding Corporation
$48.00
▲ 6.93%
Prev close $44.89
Nov 18, 2026 ET
⚡Material / Earnings✓High confidence

What changed: Scholar Rock Holding Corporation (SRRK) moved +6.93% on November 18, 2026, following management presentations at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference. At Jefferies on November 17, management highlighted strong early demand for ISEMBYLD (apitegromab-mstn), the company's FDA-approved spinal muscular atrophy therapy, despite typical rare-disease launch challenges around reimbursement and billing codes.

Source: daily_prices:fmp_change_percent

Changes History →
What's next

Q3 2026 results (reported November 10) showed $0.57 million in revenue and a $205 million PRV sale; watch for Q4 revenue and ISEMBYLD patient uptake metrics in the next earnings report scheduled for March 2, 2027.

Latest research

View all research →

In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.

Target (TGT) share-price line rising toward a 52-week high on an abstract background, marking a traffic-led fiscal Q3 earnings beat and raised sales guidance.
Stock AnalysisNovember 18, 2026 · 11 min read

Target (TGT) Jumps Toward a 52-Week High on a Traffic-Led Q3 Beat and a Raised Sales Outlook

Target (TGT) jumped more than 5% on November 18, pushing toward its 52-week high after a traffic-led fiscal third-quarter beat — a gain that substantially outpaced flat big-box peers and the broad market. EPS of $2.65 (GAAP and adjusted alike) cleared the ~$2.07 expected, but about $0.50 came from a one-time $301 million tariff refund, leaving underlying EPS near $2.15 (still up ~21% year over year). What mattered more was the mix: comparable sales rose 5.6%, driven by a 5.0% gain in traffic — more shoppers, the proof point for a company whose slump was a traffic problem — though the category recovery stayed uneven, with apparel and home soft. Target also raised its full-year sales-growth outlook to around 6%. The catch is price: after more than doubling off an $83 low, the stock sits near its 52-week high and above the analysts' average target of ~$165.56, with only a Hold consensus, so much of the initial re-rating may already be reflected and the holiday quarter now has to confirm the recovery.

Walt Disney (DIS) share-price line rising toward a 52-week high on an abstract background, marking a fiscal Q4 earnings beat, doubled streaming profit, and a dividend increase.
Stock AnalysisNovember 17, 2026 · 11 min read

Disney (DIS) Nears a 52-Week High on a Q4 Beat, a 33% Dividend Hike, and a $3 Billion Savings Target

The Walt Disney Company rose about 2.5% to roughly $122 — within about 1% of a 52-week high — on November 17 after reporting fiscal fourth-quarter results, outperforming flat media peers and the broader market. Revenue rose 16% to $25.9 billion (though an extra 53rd week flatters that to roughly 8% underlying) and adjusted EPS of $1.77 beat expectations, with the standout being streaming: operating income more than doubled to $824 million (about +65% excluding the extra week), confirming the direct-to-consumer business is becoming meaningfully profitable. Management paired the beat with a shareholder-friendly message — a 33% dividend increase (to $2.00 a year) and a target of about $3 billion in annual cost savings by fiscal 2029 — while reaffirming double-digit adjusted-EPS growth in fiscal 2027 and, notably, raising content spending ~9% to roughly $26 billion, so this is still a growth-and-invest story. The turnaround, initiated under Bob Iger and now led by CEO Josh D'Amaro, is clearly working — but the catch is price: the stock has risen ~14% in a year to near its 52-week high, with only ~5% upside to the average analyst target, so much of it is already in the shares.

A deep-navy data card reading 'DoorDash + Instacart, $17B deal meets the DOJ' with the tickers DASH and CART, a number line showing Instacart's $58.66 price below the $65 offer, and an antitrust-gavel motif, marking the DOJ-led review of the acquisition.
Stock AnalysisNovember 17, 2026 · 9 min read

DoorDash's $17 Billion Instacart Takeover Heads to a DOJ Antitrust Review

DoorDash's roughly $17 billion, $65-a-share acquisition of Instacart now heads to a U.S. Department of Justice antitrust review, Reuters and Bloomberg reported — the DOJ, not the FTC, taking the lead on a deal to combine the top restaurant-delivery and online-grocery platforms. A review is not a challenge, and both companies still target a late-2027/early-2028 close, but with CART near $59 versus the $65 offer, the ~11% spread tells the real story: time, regulatory risk, and a stock-heavy slice of the consideration that floats with a falling DoorDash.

DASHCARTRead →
Summit Therapeutics (SMMT) share-price line falling sharply on an abstract background, marking an FDA Complete Response Letter for ivonescimab.
Stock AnalysisNovember 16, 2026 · 12 min read

Summit Therapeutics (SMMT) Plunges ~16% to a 52-Week Low After the FDA Rejects Ivonescimab's First US Filing

Summit Therapeutics plunged about 16% to roughly $11.82 — a fresh 52-week low — on November 16 after disclosing that the FDA had issued a Complete Response Letter (a rejection, for now) for its lead drug, ivonescimab. The move was emphatically company-specific: on a day the broad market and biotech indexes each fell about 2%, Summit dropped eight times as hard. The CRL covers ivonescimab plus chemotherapy after EGFR-targeted treatment in non-small cell lung cancer, from the Phase 3 HARMONi trial — which clearly met its progression-free survival goal (6.8 vs 4.4 months) but whose primary overall-survival analysis narrowly missed significance (16.8 vs 14.0 months, HR 0.79, p=0.057), and the FDA judged the benefit-risk insufficient. Crucially, this is not a verdict that the drug fails to extend life: in a separate first-line trial (China's HARMONi-2) ivonescimab beat Keytruda on overall survival (30.8 vs 22.6 months, HR 0.73, p=0.009). Several things keep the CRL from being thesis-ending: it covers one smaller indication; the far larger global first-line opportunity (HARMONi-3, HARMONi-7) is still ahead; and just six weeks earlier AstraZeneca completed a $2 billion strategic investment in Summit. Even after the drop, Summit is a ~$9.4 billion company with roughly $2.6 billion of liquidity (including the AstraZeneca cash) and ~27%-of-float short interest — a well-funded, AstraZeneca-backed, polarizing bet whose value rests almost entirely on first-line survival data still to come.

Tyson Foods (TSN) share-price line rising on an abstract background, marking a better-than-feared Q4 and a 2027 beef-recovery outlook.
Stock AnalysisNovember 16, 2026 · 11 min read

Tyson Foods (TSN) Jumps ~7% on a Better-Than-Feared Q4 and an Outlook for Sharply Narrower Beef Losses

Tyson Foods jumped about 7% to roughly $62.80 on November 16 after reporting fiscal fourth-quarter results — and it did so on a risk-off day, with the S&P 500 down nearly 2% as the AI, chip and crypto trades sold off. For a defensive consumer-staples name to rise ~7% while the market fell is a clear company-specific signal, reinforced by a rotation into cheap, low-beta stocks. Tyson's adjusted EPS of $0.61 was roughly in line with or slightly above commonly cited consensus estimates, but it was down ~47% year over year, and on a GAAP basis the company posted a $0.22-per-share loss; revenue of $14.6 billion beat but underlying sales fell ~4%, and adjusted operating income dropped 41%. What drove the jump was the outlook — specifically for beef: management guided its Beef segment from a $654 million fiscal-2026 loss toward roughly breakeven in 2027 (a $300 million loss to a $100 million profit), a sharp narrowing of the biggest drag on earnings caused by a historic cattle shortage, even though total-company adjusted operating-income guidance ($1.7–$2.15 billion) is roughly flat versus this year's $1.977 billion. The stock looks cheap on sales (~0.4x) and reasonable on forward earnings (~16x), but after the pop it sits right at the analysts' average target with a Hold rating — so the move reads as a weak-but-better-than-feared quarter plus a credible beef-loss turn, re-rating a beaten-down defensive in one session.